Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas.

Authors
Corazzelli, Gaetano 
Frigeri, Ferdinando 
Arcamone, Manuela 
Capobianco, Gaetana 

Loading...
Thumbnail Image
Type
Article
Change log
Abstract

Patients with recurring T-cell non-Hodgkin lymphoma (T-NHL) are incurable and candidate for investigational agents. Here, we report on five patients with T-NHL refractory to multiple chemotherapy lines, including in all cases alkylators and gemcitabine, who received the third-generation chloroethylnitrosourea fotemustine at a dose of 120 mg/m(2) every 21 d, up to eight courses. Median actual dose intensity was 79%; toxicity was manageable and mainly hematological. One complete remission, one partial remission, two protracted disease stabilization, and one transient, minor response were achieved. Time to progression ranged from 48 to 240+ d. This is the first evidence ever reporting the activity of fotemustine in end-stage T-NHL. Formal studies with this agent are warranted in T-cell malignancies.

Publication Date
2011-12
Online Publication Date
2011-07-31
Acceptance Date
Keywords
Aged, Antineoplastic Agents, Alkylating, Humans, Lymphoma, T-Cell, Middle Aged, Nitrosourea Compounds, Organophosphorus Compounds
Journal Title
Eur J Haematol
Journal ISSN
0902-4441
1600-0609
Volume Title
87
Publisher
Wiley
Rights
Publisher's own licence